Six science items: PIM and dual A2A/A2B inhibitors, anti-target docking/FEP for lead optimization, a covalent MKRN2 glue, a brain-penetrant covalent NLRP3 inhibitor and STAT6 benzimidazoles. Business: Roche–Zymeworks, Gilead–PepStar, Pathos's raise and Alnylam's Huntington's plan.
2026-10-22 · ⚗️A2A/A2B adenosine receptors / dual small-molecule antagonist · Journal of Medicinal Chemistry
- Imidazo[1,2-a]pyrazine-ureas emerged as a new chemotype of dual A2A/A2B adenosine receptor antagonists.
- SAR showed that iodination at the 3-position of the core improved affinity and functional antagonism; simulations suggest distinct binding modes in the two orthosteric pockets.
- The lead restored T-cell cytokine production, increased T-cell infiltration, and boosted anti-PD-1 efficacy in CD73-high colorectal models.
💡 PointsDual A2A/A2B blockade makes sense in CD73-high tumors, where adenosine hits both receptors, but A2B selectivity versus A1 and A3 is usually the hard part. A 3-iodo group is a flag for me: it helps affinity but invites questions about metabolic stability and lipophilic efficiency. Whether the iodine can be swapped for a smaller or less lipophilic group is the next experiment.
Imidazo[1,2-a]pyrazine Derivatives as Dual A2A/A2B Adenosine Receptor Antagonists Enhancing Anti-PD-1 Antibody Therapy in Colorectal Cancer ↗
2026-10-22 · ⚗️PIM-1/2/3 kinases / small-molecule inhibitor · Journal of Medicinal Chemistry
- Merging the clinical PIM inhibitor PIM447 with a second PIM chemotype (C28) gave a pyridine-dihydropyrrolopyrrolidone series.
- The lead blocks all three PIM isoforms, cuts phosphorylation of substrates such as BAD, and drives apoptosis and G2/M arrest in an AML cell line.
- It was selective across a ~200-kinase panel, orally bioavailable, and suppressed tumor growth in an AML xenograft with lower platelet toxicity than C28.
💡 PointsPlatelet toxicity is what has kept PIM inhibitors from being dosed hard enough, so a hybrid that improves that margin is the interesting part, not the potency. I'd want to see whether the gain comes from isoform balance or simply lower exposure in marrow. Without data in genetically varied AML models, I'd treat this as a promising scaffold rather than a settled lead.
Discovery of Novel Pyridine-Dihydropyrrolo[3,4-b]Pyrrolidone Derivatives as Orally Active PIM Kinase Inhibitors for the Treatment of Acute Myeloid Leukemia ↗
2026-10-22 · ⚗️STAT6 / direct small-molecule inhibitor · ACS Medicinal Chemistry Letters
- This patent highlight describes substituted benzimidazoles from Belharra Therapeutics that directly inhibit STAT6.
- STAT6 relays IL-4 and IL-13 signaling into type 2 inflammatory programs behind allergic disease.
- Compounds show submicromolar biochemical activity, pointing to possible oral, pathway-focused alternatives to extracellular IL-4/IL-13 biologics.
💡 PointsTranscription factors are the hard end of tractability, so a patent that credibly shows direct STAT6 engagement is worth tracking even at submicromolar potency. Biochemical activity is the easy half; whether these compounds reach cellular target engagement and avoid other STATs is what decides it. The comparison to dupilumab-class biologics is a long way off.
Direct STAT6 Inhibition: Benzimidazoles Move Type 2 Inflammation Downstream ↗
2026-10-20 · 🧬NLRP3 inflammasome / covalent allosteric inhibitor · British Journal of Pharmacology2026, 183 (22), 6718-6734
- Chemoproteomic profiling was used to find a covalent NLRP3 inhibitor.
- The compound is brain-penetrant and is described as binding a previously unreported allosteric pocket.
- Only the title and issue details were accessible when this was written, so potency, selectivity and efficacy data are not covered.
💡 PointsNLRP3 has plenty of reversible MCC950-type chemistry, so the interest here is a different pocket and a route in neuroinflammation via brain exposure. Covalent warheads in a CNS drug still need clean proteome-wide selectivity, and the residue targeted matters for resistance and species translation. A new pocket gives other groups a second place to design against.
Chemoproteomic discovery of a brain-penetrant, covalent NLRP3 inhibitor that binds a novel allosteric pocket ↗
2026-10-20 · 🧬MKRN2 E3 ligase / covalent molecular glue degrader · British Journal of Pharmacology2026, 183 (22), 6663-6684
- A covalent molecular glue is reported to engage the E3 ligase MKRN2 and drive degradation of the ribosomal protein RPS7.
- The effect induces synthetic lethality in p53-deficient non-small cell lung cancer cells.
- Only the title and issue details were accessible when this was written, so mechanistic and in vivo details are not covered here.
💡 PointsTwo things stand out: the E3 is MKRN2, far from the usual CRBN/VHL set, and the substrate is a ribosomal protein, so the p53-deficient dependency is a stress-pathway story rather than classic target loss. Covalent engagement of a non-canonical ligase is attractive for novelty but raises selectivity-proteomics questions I'd want answered before taking it seriously.
A covalent molecular glue hijacks the E3 ligase MKRN2 to degrade the ribosomal protein RPS7 and induce synthetic lethality in p53-deficient NSCLC cells ↗
2026-10-23 · 🏢Clinical update (RNAi, Huntington's disease) · BioSpace · Alnylam Pharmaceuticals
- Alnylam will advance its Huntington's disease RNAi drug brezosiran into a placebo-controlled study in 2027.
- Timing depends on first reaching regulatory alignment.
- BioSpace's headline describes the data as ‘best-in-class knockdown’; detailed figures were not in the feed text.
💡 PointsKnockdown of huntingtin is only the first hurdle; the pivotal trial will have to show clinical benefit, and that is where HTT-lowering programs have stumbled before. The regulatory-alignment caveat means the endpoint question is open. For the RNAi field, a CNS indication with strong target engagement would extend Alnylam's case beyond liver-centric products.
Alnylam plans pivotal trial as Huntington’s drug notches ‘best-in-class knockdown’ ↗
2026-10-23 · 🏢License (inflammation & immunology program) · BioSpace · Gilead Sciences / PepStar Therapeutics
- Gilead has picked up a new inflammatory disease program from China's PepStar Therapeutics.
- It is meant to pair with Gilead's Phase 2 inflammatory bowel disease asset emvistegrast.
- BioSpace's headline cites a $1.3 billion figure; the modality and the financial breakdown were not available from the feed text.
💡 PointsPutting an IL-23 asset next to emvistegrast reads as a bid for combination or sequencing in IBD, where single-pathway drugs plateau. Another China-originated I&I license also fits the trend of Western pharma buying early. Until the payment split is clear, the headline figure tells us little about how much Gilead is actually committing.
Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar ↗
2026-10-23 · 🏢Financing and partnership · Endpoints News · Pathos AI / Bristol Myers Squibb
- AI-driven biotech Pathos AI raised a $237 million Series E at a $3 billion valuation.
- Endpoints notes the round came in below the $300 million the company had been associated with.
- The company also signed a neuroscience partnership with Bristol Myers Squibb; terms were not in the feed text.
💡 PointsA $3B valuation on a sub-target raise suggests investors still pay up for AI-biotech, but not at any size. The BMS neuro tie-up matters more as validation: big pharma seems to prefer partnering on difficult CNS biology to buying platforms outright. I'd watch whether the deal carries real milestones or just platform fees.
Pathos raises $237M at $3B valuation, signs Bristol Myers neuro partnership ↗
2026-10-23 · 🏢License (preclinical trispecific T cell engager) · Endpoints News · Roche / Zymeworks
- Roche will pay Zymeworks $55 million upfront for worldwide rights to a preclinical trispecific T cell engager.
- Total potential value is up to $813 million.
- Endpoints notes the molecule could go head-to-head with Amgen's Imdelltra.
💡 PointsA $55M upfront on an $813M headline for a preclinical asset is a standard option-style structure: Roche pays little until the molecule proves itself. The interesting angle is the benchmark, since pointing at Imdelltra implies a DLL3-type small cell lung cancer ambition. For Zymeworks it validates the multispecific platform without the cost of clinical development.
Roche taps Zymeworks in up to $813M deal for preclinical T cell engager ↗
